Article articulates how founder Jason Ruegg has profitably grown the business from a college side-hustle to America’s largest pre-owned boat company Wilmington, NC, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Off The Hook YS Inc. (NYSE American: OTH) (“Off the Hook Yachts” or “Off the Hook” or “the Company”), America’s largest buyer and seller of pre-owned boats, today announced the publication of an article titled “How a yacht-flipping business went from college side hustle to $68M publicly traded company” in the N ...

Core Insights - Citius Oncology has launched LYMPHIR, a novel immunotherapy for treating relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL) in the U.S. as of December 2025, marking a significant transition from a pre-revenue to a revenue-generating company [1][2][6] Business Highlights - The company has executed service agreements with three leading U.S. pharmaceutical wholesalers to distribute LYMPHIR to various healthcare organizations [6] - Citius Oncology has secured access to LYMPHIR in 19 international markets through regional distribution partners via Named Patient Programs, initiating its global access strategy [6] - A collaboration with Verix has been announced to utilize its Tovana AI-powered platform for enhancing commercial targeting and provider engagement [6] - Preliminary results from a Phase I clinical trial combining pembrolizumab and LYMPHIR in cancer patients have shown promise [6] Financial Highlights - Citius Oncology completed $36 million in strategic financings, including an $18 million private placement and registered direct offering on December 10, 2025 [1][4] - As of September 30, 2025, the company reported cash and cash equivalents of $3.9 million, with a net loss of $24.8 million, or ($0.34) per share, compared to a net loss of $21.1 million, or ($0.31) per share for the previous fiscal year [4][12] - Research and development expenses increased to $6.4 million for the fiscal year ended September 30, 2025, up from $4.9 million in the prior year [4][12] Market Potential - The initial market for LYMPHIR is estimated to exceed $400 million and is considered underserved by existing therapies, indicating significant growth potential [7] - The company holds robust intellectual property protections, including orphan drug designation and pending patents, which support its competitive positioning in the oncology market [7]